Next Science (ASX:NXS) granted its first acne-related patent

Company News

by Katrina Bullock

The US Patent Office has granted Biotech company Next Science (ASX:NXS) a patent for the application of Next Science’s unique XbioTM technology in its Acne gels and creams.

The company’s proprietary XbioTM technology platform is used in the treatment of biofilm-based infections, such as acne.

Next Science says that “[t]his new patent provides [it] with a unique platform for the purpose of commercialisation and licensing in the field of acne treatment, in addition to the other technologies in its product portfolio”.

Next Science’s wholly owned subsidiary, Next Science IP Holdings now owns 22 patents granted by authorities in the United States, Australia, Europe, Japan and Canada.

Shares in Next Science (ASX:NXS) are trading 9.5 per cent higher at $1.84.

Katrina Bullock

Finance News Network
Katrina is a respected TV journalist, as well as a renowned presenter and award winning lawyer. She holds a Bachelor of Laws (Honours 1st class, division 1), a Bachelor of Business (with Distinction) and is currently undertaking a PhD in Law focused on stock exchange disclosures and corporate governance. She began her career as a corporate lawyer in an Australian top tier commercial law firm and is currently the General Counsel of Greenpeace Australia Pacific. In 2020 Katrina was named one of the 30 best lawyers in Australia under 30 by Lawyer's Weekly.